Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
58.99(c) 54.56(c) 54.14(c) 54.88(c) 53.83 Last
87 082 370 857 117 570 76 089 148 647 Volume
-0.86% -7.51% -0.77% +1.37% -1.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -71,8 M - -
Net cash position 2021 376 M - -
P/E ratio 2021 -30,2x
Yield 2021 -
Sales 2022 0,43 M - -
Net income 2022 -101 M - -
Net cash position 2022 342 M - -
P/E ratio 2022 -21,3x
Yield 2022 -
Capitalization 2 172 M 2 172 M -
EV / Sales 2021 -
EV / Sales 2022 4 223x
Nbr of Employees 29
Free-Float 61,6%
More Financials
Company
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic... 
Sector
Biotechnology & Medical Research
Calendar
11/12 | 07:00amPresentation
More about the company
Ratings of ALX Oncology Holdings Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about ALX ONCOLOGY HOLDINGS INC.
10:23aALX ONCOLOGY : Says First Patient Dosed in Study for Acute Myeloid Leukemia Treatment
MT
07:01aALX ONCOLOGY : Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept ..
GL
10/19INSIDER SELL : Alx Oncology Holdings
MT
10/07ALX ONCOLOGY : Buys ScalmiBio
MT
10/07ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio (Form 8-..
PU
10/07ALX ONCOLOGY HOLDINGS INC : Unregistered Sale of Equity Securities, Other Events, Financia..
AQ
10/07ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
AQ
10/07ALX Oncology Holdings Inc. acquired ScalmiBio Inc from Jaume Pons and others for $41.5 ..
CI
10/05ZYMEWORKS : ALX Oncology Say Dosing Initiated in Clinical Study of Antibody Drug for Certa..
MT
10/05ALX ONCOLOGY : Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clini..
PU
10/05ALX ONCOLOGY : Corporate Presentation, October 5, 2021
PU
10/01ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immu..
GL
09/30ALX ONCOLOGY : Advances Amid Thin Volume After Stifel Initiates Stock With Buy Rating
MT
09/30ALX ONCOLOGY : Stifel Starts ALX Oncology Holdings at Buy With $106 Price Target
MT
09/20INSIDER SELL : Alx Oncology Holdings
MT
More news
News in other languages on ALX ONCOLOGY HOLDINGS INC.
10:23aALX Oncology annonce l'administration d'une dose à un premier patient dans le cadre d'u..
10/05Zymeworks et ALX Oncology annoncent le début du dosage dans l'étude clinique d'un antic..
09/30ALX Oncology progresse dans un volume faible après que Stifel ait initié le titre avec ..
05/07EQS-ADHOC : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen Jahresgewi..
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | ALXO | US00166B1052 | MarketScreener
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 53,83 $
Average target price 98,38 $
Spread / Average Target 82,8%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-36.33%2 214
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.77%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121